{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-007719","form_type":"8-K","ticker":"AEMD","cik":"0000882291","company_name":"AETHLON MEDICAL INC","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.840855+00:00","generated_at":"2026-06-21T21:52:36.504760+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aethlon reports Q2 net loss $3.8M; terminates COVID trial, launches Australia sub","bullets":["Cash balance $19.6M as of Sep 30, 2022; operating expenses $3.67M, up 71% YoY.","Terminated US COVID trial due to scarce ICU patients; expects $5M savings over 12 months.","Launched wholly owned Australian subsidiary in Oct 2022 to conduct oncology studies.","Dissolved Exosome Sciences, Inc., recording $142K non-cash charge in Q2.","Raised ~$8.9M net proceeds from ATM stock sales in H1 fiscal 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-007719","json":"https://secwatch.observer/filing/0001683168-22-007719.json","markdown":"https://secwatch.observer/filing/0001683168-22-007719.md","text":"https://secwatch.observer/filing/0001683168-22-007719.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882291/000168316822007719/0001683168-22-007719-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882291/000168316822007719/aethlon_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T21:52:36.504760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9cf6a62b1fba2cbee9ecdbd09eb7d17eea4093ab","claim":"AETHLON MEDICAL INC reported its second quarter ended September 30, 2022 results: net income approximately $3.8 million.","evidence_excerpt":"As a result of the changes in revenues and expenses noted above, our net loss increased to approximately $3.8 million in the three months ended September 30, 2022, from approximately $2.0 million in the three months ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882291/000168316822007719/0001683168-22-007719-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"its second quarter ended September 30, 2022"},{"label":"Net income","value":"approximately $3.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}